NA
MYGN icon

NewEdge Advisors’s Myriad Genetics MYGN Stock Holding History

NewEdge Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Buy
+52,385
New +$238K ﹤0.01% 2494
2021
Q4 		– Sell
-8,882
Closed -$287K – 1677
2021
Q3 		$287K Buy
8,882
+334
+4% +$11.1K 0.01% 917
2021
Q2 		$261K Buy
+8,548
New +$247K 0.01% 962

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's MYGN Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Myriad Genetics (MYGN) in Q2 2026: 52,385 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #2494 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in MYGN as recently as Q3 2021.

NewEdge Advisors first reported a position in MYGN in Q2 2021 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • NewEdge Advisors held 52,385 shares of Myriad Genetics worth $299K as of Q2 2026.
  • Myriad Genetics was a new NewEdge Advisors position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2494 holding.
  • NewEdge Advisors first reported a position in Myriad Genetics in Q2 2021 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.